Labtest Diagnóstica has been sold to Virtue Diagnostics
Founded in 1971, Labtest Diagnóstica is a pioneer and one of the largest in vitro diagnostic (IVD) solutions provider in Brazil, establishing itself as a reference in the biotechnology market and recognized nationally and internationally. Labtest develops, manufactures and sells IVD products from its 5,100m² best-in-class manufacturing facility in Minas Gerais with a portfolio comprising a wide range of reagents and equipments (more than 300) focused on offering solutions integrated with continuing education programs and permanent technical and scientific assistance for clinical laboratories, health care units and hospitals.
Labtest’s more than 230 employees will now be joined by Virtue Diagnostics, a global, fast growing platform-based IVD solutions provider with intensive research and development (R&D) and state-of-the-art IVD facilities. The acquisition follows Virtue’s strategy of expansion in emerging markets, establishing a leading platform in Brazil, and offering growth and expansion opportunities for Labtest, including an increase in production capacity, the possibility of reaching new markets in Brazil and internationally and the broadening of the product portfolio.
Luiz Recchia, Managing Director in Lincoln’s São Paulo office, commented, “This landmark transaction highlights Lincoln´s expertise in dealing with complex situations, including a diverse shareholder base, a foreign buyer and a changing healthcare market environment post-COVID-19. With Virtue, Labtest will have access to new products, new methodologies and an opportunity to consolidate its leadership in the Brazilian market even further.”
Founded in 2019, Virtue Diagnostics is a global, platform-based IVD solutions provider focusing on affordable clinical solutions at all disease stages including very early screening, initial diagnosis, treatment monitoring and minimal residual disease management. Virtue Diagnostics Corporate and R&D headquarters are in Singapore, manufacturing is in Suzhou, China and CRO / Clinical Lab is in Beijing.
Meet our Senior Team
My approach with our bankers and clients is to listen, pay attention to detail, anticipate and keep an eye on the big picture.
Managing Director | CEO BrazilSão Paulo
View More Transactions in Healthcare
Lincoln International advised Medisolv on receiving a strategic investment from BVP Forge
Lincoln International advised Millbrook Healthcare Group on the sale of Ross Care to Medequip, a subsidiary of Medux
Lincoln International advised Standard Investment on the sale of Dierenartsen Groep Nederland to VetPartners, a portfolio company of BC Partners
Lincoln International advised Syst'am, a portfolio company of Meanings Capital Partners, on the acquisition of Järven Health Care
Lincoln International advised Alaris Equity Partners, in partnership with Brookfield Special Investments, on raising $546 million in equity and $180 million in debt for Sono Bello
Lincoln International advised kiana group in its sale to Kalaidos, a subsidiary of Klett Group
Lincoln International advised Grant Avenue Capital in its launch with Helios Clinical Research
Any information or testimonials contained in this post may not be representative of the experience of other clients and is no guarantee of future performance or success.